Company intelligence / Profile preview

Shanghai Scizeng Medical Technology Co., Ltd.

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

GenSci098 (GS-098), a first-in-class humanized monoclonal antibody targeting TSHR, has received IND approvals for clinical trials in China (August 2024 for TED, October 2025 for GD) and implied FDA IND clearance in the US.

Therapeutic areas: Endocrinology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Yarrow Bioscience, Inc.RTW Investments, LP

Beyond the preview

Go deeper on Shanghai Scizeng Medical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Scizeng Medical Technology Co., Ltd..

Explore the full profile